Pulmonary Embolism Medical Services in China

Pulmonary embolism (PE) is a potentially life-threatening cardiovascular condition caused by the obstruction of one or more pulmonary arteries—most commonly by thrombi originating from deep vein thrombosis (DVT) in the lower extremities. Clinical presentation ranges from asymptomatic to acute respiratory distress, pleuritic chest pain, hemoptysis, tachycardia, and hemodynamic instability in massive PE. Diagnosis relies on clinical assessment (e.g., Wells score), D-dimer testing, and confirmatory imaging—primarily CT pulmonary angiography (CTPA) or ventilation-perfusion (V/Q) scintigraphy. Management encompasses risk-stratified anticoagulation (e.g., direct oral anticoagulants or low-molecular-weight heparin), reperfusion therapy (thrombolysis or catheter-directed thrombectomy) for high-risk cases, and long-term secondary prevention to mitigate recurrence.

China offers distinct advantages for PE management: its tertiary hospitals—especially those affiliated with top-tier universities—house nationally certified cardiovascular centers with extensive experience in complex thromboembolic disease. Advanced interventional capabilities include real-time 3D rotational angiography, intravascular ultrasound (IVUS), and mechanical thrombectomy platforms approved by both NMPA and CE. Published outcomes demonstrate >92% technical success in catheter-based interventions for submassive and massive PE, with mortality rates aligned with international benchmarks. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or multidisciplinary care pathways.

As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients—handling hospital referrals, coordinating specialist consultations, verifying transparent all-inclusive pricing, arranging visas and accommodations, and providing bilingual clinical support throughout diagnosis, treatment, and follow-up.

Treatment Options & Itemized Cost Breakdown: Pulmonary Embolism (Cardiology Department)

Non-Surgical / Conservative Management

*Indicated for low- to intermediate-risk PE without hemodynamic instability, contraindications to anticoagulation, or stable chronic thromboembolic pulmonary hypertension (CTEPH).*

• •Anticoagulation Therapy (First-Line)

- *Itemized Costs (USD, Grade 3A Hospital):* - LMWH (enoxaparin, 7-day course): $180–$240 - DOAC (rivaroxaban/apixaban, 3-month course): $320–$460 - Warfarin + INR monitoring (3 months): $110–$150 (includes 12 PT/INR tests @ $9 each) - *Required Baseline Exams:* D-dimer ($22), CBC ($12), renal function ($18), liver panel ($24), ECG ($15), chest X-ray ($28) → Total: $119

Surgical / Procedural / Interventional Options

*Eligibility strictly requires high-risk PE (systolic BP <90 mmHg, cardiac arrest, or persistent shock) or intermediate-high-risk with clinical deterioration despite anticoagulation.*

• •Catheter-Directed Thrombolysis (CDT)

- *Procedure Fee:* $3,800–$5,200 (includes catheterization, urokinase/tPA infusion, ICU monitoring × 48h) - *Preoperative Workup:* CT pulmonary angiography ($145), echocardiogram ($85), arterial blood gas ($26), coagulation panel ($32) → Total: $288

• •Surgical Pulmonary Embolectomy

- *Procedure Fee:* $8,900–$11,400 (CPB, sternotomy, ICU × 5 days) - *Preoperative Workup:* Same as CDT + transthoracic echo ($85), ABG ($26), crossmatch ($42) → Total: $375

Special / Complex Condition Management

• •Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

- *Balloon Pulmonary Angioplasty (BPA):* $4,500–$6,300 per session, typically 2–4 sessions ($9,000–$25,200 total)

Quick Selection Guide

• •Young, Low-Risk, Budget-Conscious (<60 yrs, no comorbidities): DOAC monotherapy ($320–$460) + baseline labs ($119)
• •Elderly, Renal Impairment (eGFR 30–60 mL/min): LMWH + renal-adjusted dosing ($240) + extended monitoring ($119)
• •High-Risk, Shocked Patient: Immediate CDT ($3,800–$5,200) — avoids surgical risk and reduces mortality vs. delayed surgery
• •CTEPH Confirmed: PEA at specialized center ($14,200–$17,600) — superior long-term survival vs. medical therapy alone
• •Contraindicated to All Thrombolytics/Surgery: Inferior vena cava filter placement ($2,100–$2,900) + lifelong anticoagulation ($320–$460/year)